Evelo Biosciences - EVLO Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.38
  • Forecasted Upside: 705.92 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.28
▲ +0.02 (0.88%)

This chart shows the closing price for EVLO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Evelo Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for EVLO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for EVLO

Analyst Price Target is $18.38
▲ +705.92% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Evelo Biosciences in the last 3 months. The average price target is $18.38, with a high forecast of $41.50 and a low forecast of $4.00. The average price target represents a 705.92% upside from the last price of $2.28.

This chart shows the closing price for EVLO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Evelo Biosciences. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/13/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/12/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/10/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/8/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/8/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/7/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/5/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/9/2022Morgan StanleyLower TargetEqual Weight$5.00 ➝ $4.00Low
8/24/2022Morgan StanleyLower TargetEqual Weight$6.00 ➝ $5.00Low
8/15/2022Chardan CapitalLower TargetBuy$12.00 ➝ $5.00Low
11/2/2021JMP SecuritiesLower TargetMarket Outperform$44.00 ➝ $41.50High
11/1/2021Chardan CapitalUpgradeNeutral ➝ Buy$12.00Medium
10/31/2021BMO Capital MarketsReiterated RatingBuy$23.00Medium
9/28/2021Jefferies Financial GroupLower TargetBuy$18.00 ➝ $14.00High
9/27/2021JMP SecuritiesReiterated RatingBuy$44.00Medium
7/30/2021Chardan CapitalLower TargetNeutral$15.00 ➝ $12.00High
7/9/2021Chardan CapitalInitiated CoverageHold$15.00Low
7/1/2021Chardan CapitalReiterated RatingNeutralLow
6/23/2021JMP SecuritiesBoost TargetPositive ➝ Market Outperform$36.00 ➝ $38.00High
6/23/2021Cantor FitzgeraldInitiated CoverageOverweight$28.00High
5/3/2021Morgan StanleyLower TargetEqual Weight$14.00 ➝ $13.00High
4/12/2021Jefferies Financial GroupUpgradeHold ➝ Buy$11.00 ➝ $18.00High
3/12/2021Chardan CapitalBoost TargetNeutral$10.00 ➝ $15.00Low
1/25/2021JMP SecuritiesBoost TargetPositive ➝ Outperform$27.00 ➝ $36.00High
1/19/2021Morgan StanleyBoost TargetEqual Weight$6.00 ➝ $14.00Low
12/23/2020JMP SecuritiesInitiated CoverageOutperform$27.00 ➝ $27.00N/A
11/11/2020Morgan StanleyLower TargetEqual Weight$8.00 ➝ $6.00Low
7/2/2020BMO Capital MarketsLower TargetOutperform$21.00 ➝ $17.00Medium
5/21/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$8.00Medium
5/12/2020BMO Capital MarketsLower TargetOutperform$24.00 ➝ $21.00High
5/12/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$18.00 ➝ $6.00High
3/20/2020Chardan CapitalReiterated RatingHoldHigh
2/14/2020CowenReiterated RatingBuyHigh
9/19/2019Chardan CapitalReiterated RatingNeutralHigh
5/2/2019CowenReiterated RatingBuyLow
5/2/2019Chardan CapitalReiterated RatingHold$10.00Low
4/30/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$18.00Medium
2/15/2019Chardan CapitalReiterated RatingHold$10.00Medium
1/29/2019Chardan CapitalInitiated CoverageNeutral$10.00Low
12/3/2018JMP SecuritiesReiterated RatingBuy$25.00High
10/11/2018Morgan StanleyBoost TargetOverweight$29.00 ➝ $30.00Low
6/4/2018CowenInitiated CoverageOutperformLow
6/4/2018Morgan StanleyInitiated CoverageOverweightLow
6/4/2018BMO Capital MarketsInitiated CoverageOutperform$26.00Low
6/4/2018JMP SecuritiesInitiated CoverageOutperform$25.00Low
(Data available from 10/5/2017 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/9/2022
  • 0 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/8/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/7/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 2 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
9/5/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/5/2022

Current Sentiment

  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Evelo Biosciences logo
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $2.28
Low: $2.17
High: $2.32

50 Day Range

MA: $2.30
Low: $1.86
High: $3.01

52 Week Range

Now: $2.28
Low: $1.42
High: $12.74

Volume

1,483 shs

Average Volume

244,605 shs

Market Capitalization

$246.22 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.45

Frequently Asked Questions

What sell-side analysts currently cover shares of Evelo Biosciences?

The following equities research analysts have issued stock ratings on Evelo Biosciences in the last twelve months: BMO Capital Markets, Chardan Capital, JMP Securities, and Morgan Stanley.
View the latest analyst ratings for EVLO.

What is the current price target for Evelo Biosciences?

4 Wall Street analysts have set twelve-month price targets for Evelo Biosciences in the last year. Their average twelve-month price target is $18.38, suggesting a possible upside of 705.9%. JMP Securities has the highest price target set, predicting EVLO will reach $41.50 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $4.00 for Evelo Biosciences in the next year.
View the latest price targets for EVLO.

What is the current consensus analyst rating for Evelo Biosciences?

Evelo Biosciences currently has 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe EVLO will outperform the market and that investors should add to their positions of Evelo Biosciences.
View the latest ratings for EVLO.

What other companies compete with Evelo Biosciences?

How do I contact Evelo Biosciences' investor relations team?

Evelo Biosciences' physical mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The company's listed phone number is (617) 577-0300 and its investor relations email address is [email protected] The official website for Evelo Biosciences is www.evelobio.com. Learn More about contacing Evelo Biosciences investor relations.